药物代谢学揭示了关键的代谢变化,这是首次对β-拉帕衍生物进行人体研究
Yeonseo Jang1, Jihyun Kang1,2,3, Yufei Li1
1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 101 Daehakro, Jongno-gu, Seoul, 03080, Korea.
WK0202,一个NAD(P) H氨酸脱酶1 (NQO1) 激活剂,改变了人类的新陈代谢,影响了氨基酸和脂质通路. 这些变化可能表明Nrf2通路激活,表明潜在的治疗生物标志物.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 代谢学 代谢学 代谢学
- 生物化学 生物化学
背景情况:
- WK0202是临床开发中的β-lapachone衍生物.
- 它激活NAD(P) H离子脱酶1 (NQO1),作为解毒和抗氧化剂.
- 这项研究调查了药物诱导的人类代谢途径的改变.
研究的目的:
- 为了研究由WK0202管理引起的代谢变化.
- 将这些变化与药物的治疗机制和疗效联系起来.
- 使用代谢学来识别潜在的药学动力学生物标志物.
主要方法:
- 从接受WK0202或安慰剂的健康受试者的血样本上,有针对性和非有针对性的代谢量.
- 剂前和剂后代谢概况的比较.
- 统计分析以确定显著的代谢物和途径;NQO1基因型效应的斯皮尔曼相关性.
主要成果:
- 服用WK0202显著改变了阿拉宁,阿斯巴酸盐,谷氨酸代谢,阿金氨酸生物合成和脂质代谢.
- 代谢变化显示出一致的趋势,基本上独立于NQO1的基因型或剂量.
- 观察到的变化表明Nrf2通路的激活由NQO1.1介导.
结论:
- 由WK0202引起的代谢变化可以作为替代标记物.
- 这些标记物可能有助于识别新的治疗点.
- 内源代谢物可用于评估WK0202在未来的临床研究中的疗效.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
07:54Assessing Hepatic Metabolic Changes During Progressive Colonization of Germ-free Mouse by 1H NMR Spectroscopy
Published on: December 15, 2011
相关概念视频
Drug Biotransformation: Overview
First Pass Effect
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Drug Metabolism: Phase I Reactions
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Pharmacokinetics: Overview
Factors Influencing Drug Absorption: Presystemic Elimination
